NCT05812677View on ClinicalTrials.gov

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Cervical and Endometrial Cancer

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 6, 2023

Primary Completion Date

February 6, 2025

Study Completion Date

February 6, 2026

Conditions
Cervical CancerEndometrial CancerAdvanced Cancer
Interventions
DRUG

Recombinant oncolytic herpes simplex virus type Ⅰ (R130)

R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11

Trial Locations (1)

200000

RECRUITING

Shanghai Tenth People's Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai 10th People's Hospital

OTHER

lead

Shanghai Yunying Medical Technology

INDUSTRY